Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paloma Cejas, Ph.D.

Co-Author

This page shows the publications co-authored by Paloma Cejas and Henry Long.
Connection Strength

4.612
  1. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775.
    View in: PubMed
    Score: 0.988
  2. Principles and methods of integrative chromatin analysis in primary tissues and tumors. Biochim Biophys Acta Rev Cancer. 2020 01; 1873(1):188333.
    View in: PubMed
    Score: 0.868
  3. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 06; 22(6):685-91.
    View in: PubMed
    Score: 0.678
  4. CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-seq Analysis. Genomics Proteomics Bioinformatics. 2021 Jul 17.
    View in: PubMed
    Score: 0.243
  5. FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat Protoc. 2020 08; 15(8):2503-2518.
    View in: PubMed
    Score: 0.226
  6. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Oct; 25(10):1627.
    View in: PubMed
    Score: 0.215
  7. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 08; 25(8):1260-1265.
    View in: PubMed
    Score: 0.211
  8. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021 Oct 14; 184(21):5357-5374.e22.
    View in: PubMed
    Score: 0.062
  9. An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer. Gastroenterology. 2021 Sep 25.
    View in: PubMed
    Score: 0.062
  10. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat Genet. 2021 06; 53(6):881-894.
    View in: PubMed
    Score: 0.060
  11. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
    View in: PubMed
    Score: 0.060
  12. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 Jun; 11(6):1524-1541.
    View in: PubMed
    Score: 0.059
  13. Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Sci Rep. 2020 11 18; 10(1):20135.
    View in: PubMed
    Score: 0.058
  14. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021 Jan; 2(1):34-48.
    View in: PubMed
    Score: 0.058
  15. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
    View in: PubMed
    Score: 0.058
  16. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020 10 15; 21(1):263.
    View in: PubMed
    Score: 0.058
  17. Universal NicE-seq for high-resolution accessible chromatin profiling for formaldehyde-fixed and FFPE tissues. Clin Epigenetics. 2020 09 22; 12(1):143.
    View in: PubMed
    Score: 0.057
  18. ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer. Cancer Res. 2020 11 01; 80(21):4612-4619.
    View in: PubMed
    Score: 0.057
  19. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 10 15; 80(20):4476-4486.
    View in: PubMed
    Score: 0.057
  20. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
    View in: PubMed
    Score: 0.057
  21. Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.057
  22. Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.057
  23. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8.
    View in: PubMed
    Score: 0.056
  24. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406.
    View in: PubMed
    Score: 0.055
  25. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12.
    View in: PubMed
    Score: 0.055
  26. Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Rep. 2018 11 13; 25(7):1898-1911.e5.
    View in: PubMed
    Score: 0.051
  27. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
    View in: PubMed
    Score: 0.049
  28. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.